Table 3.

Predictors of a good EULAR response to a first-line tumor necrosis factor inhibitor (TNFi), at 3 and 6 months. Univariable and multivariable analysis.

Characteristics	Univariable Analysis, 3 Months			Multivariable Analysis, 3 Months		Univariable Analysis, 6 Months			Multivariable Analysis, 6 Months
Characteristics	OR (95% CI)	p	Global p	OR (95% CI)	p	OR (95% CI)	p	Global p	OR (95% CI)	p	Global p
Age at first TNFi	0.98 (0.96–1.00)	0.094^¥				0.98 (0.96–1.00)	0.107^¥
Female	0.23 (0.13–0.41)	< 0.001^¥		0.36 (0.17–0.73)	0.005^†	0.30 (0.17–0.53)	< 0.001^¥
Obese vs other^*	0.59 (0.28–1.25)	0.166				0.37 (0.18–0.79)	0.010^¥		0.25 (0.09–0.68)	0.006^†
Axial subtype vs other^&	0.78 (0.28–2.13)	0.623				0.46 (0.17–1.25)	0.129^¥
Years of disease until first TNFi	1.04 (0.99–1.08)	0.144^¥				1.00 (0.97–1.03)	0.831
DAS28-4vESR (baseline)	0.86 (0.71–1.05)	0.146^¥				0.82 (0.67–1.01)	0.058^¥
HAQ-DI (baseline)	0.34 (0.19–0.60)	< 0.001^¥		0.44 (0.24–0.80)	0.007^†	0.47 (0.28–0.79)	0.004^¥		0.35 (0.15–0.85)	0.021^†
Concomitant corticosteroids	0.44 (0.25–0.76)	0.003^¥		0.51 (0.26–1.01)	0.054	0.38 (0.22–0.65)	0.001^¥
Concomitant csDMARD	1.56 (0.87–2.79)	0.134^¥				0.86 (0.48–1.53)	0.602
Year of starting the first TNFi	1.05 (0.96–1.15)	0.323				1.12 (1.03–1.22)	0.010^¥		1.27 (1.07–1.50)	0.006^†
Biologic therapy (ref: etanercept)
Infliximab	0.73 (0.27–1.96)	0.533	0.879			0.31 (0.11–0.86)	0.024^¥	0.002^¥	0.22 (0.04–0.74)	0.041^†	0.081
Adalimumab	0.96 (0.52–1.77)	0.901				1.68 (0.88–3.20)	0.117^¥		1.38 (0.46–4.09)	0.567
Golimumab	1.16 (0.52–2.59)	0.711				2.70 (1.14–6.41)	0.024^¥		1.50 (0.27–8.11)	0.637

↵* Obese (BMI = 30), overweight (BMI 25 to 29.9), normal (BMI 18.5 to < 24.9), underweight (BMI < 18.5).
↵& Other forms (polyarticular, oligoarticular, distal interphalangeal joints and mutilans).
↵¥ Univariable p value < 0.20.
↵† Multivariable p value < 0.05. Sample sizes at 3 months: sex (n = 218); BMI (n = 139); clinical subtype (n = 192); years of disease until first TNFi (n = 203); DAS28 (n = 218); HAQ (n = 161); concomitant corticosteroids (n = 218); concomitant csDMARD (n = 218); year of TNFi (n = 218); biologic therapy (n = 218). Multivariable analysis sample size: 161. Sample sizes at 6 months: sex (n = 217); BMI (n = 136); clinical subtype (n = 196); years of disease until first TNFi (n = 204); DAS28 (n = 217); HAQ (n = 165); concomitant corticosteroids (n = 217); concomitant csDMARD (n = 217); year of TNFi (n = 217); biologic therapy (n = 217). Multivariable analysis sample size: 101. EULAR: European League Against Rheumatism; BMI: body mass index; DAS28-4vESR: 4-variable 28-joint count Disease Activity Score using erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire–Disability Index; csDMARD: conventional synthetic disease-modifying antirheumatic drugs.